KemPharm Reports Q4 and FY 2018 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Kempharm (KMPH) PT Lowered to $8 at Oppenheimer
March 1, 2019 9:30 AM ESTOppenheimer analyst Esther Rajavelu lowered the price target on Kempharm (NASDAQ: KMPH) to $8.00 (from $10.00) while maintaining a Outperform rating.
The analyst commented, "KMPH announced 4Q results and provided an update on the business. Management is focused on KP415/KP484 development, with a... More
